We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets open in 48 mins

Onconova Therapeutics, Inc. (ONTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.5054-0.0206 (-3.92%)
At close: 4:00PM EDT
Full screen
Previous Close0.5260
Open0.5234
Bid0.5000 x 2200
Ask0.5300 x 1200
Day's Range0.5011 - 0.5390
52 Week Range0.3300 - 2.8300
Volume1,063,073
Avg. Volume2,392,271
Market Cap39.981M
Beta2.57
PE Ratio (TTM)N/A
EPS (TTM)-1.8790
Earnings DateAug 13, 2018 - Aug 17, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.45
Trade prices are not sourced from all markets
  • GlobeNewswireyesterday

    Onconova Therapeutics Announces Promotion for Steven M. Fruchtman, M.D.

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced the promotion of Dr. Steven M. Fruchtman. In his new role as President, Dr. Fruchtman will have oversight over the entire product portfolio, as well as a key role in all other areas of the Company. Dr. Fruchtman will continue to report to Dr. Ramesh Kumar, co-founder and Chief Executive Officer of the Company.

  • GlobeNewswire15 days ago

    Onconova Therapeutics Announces Presentation at the 23rd Congress of the European Hematology Association

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced a presentation at the 23rd Congress of the European Hematology Association being held June 14-17, 2018 in Stockholm, Sweden.  Dr. Steven Fruchtman, Onconova’s Chief Medical Officer and Senior VP, Research & Development, will be attending the conference. A copy of the poster and oral presentation will be available by visiting "Scientific Presentations" in the Investors section of Onconova's website immediately following the event.

  • ACCESSWIRE24 days ago

    Onconova Therapeutics, Inc. to Present at the 8th Annual LD Micro Invitational

    LOS ANGELES, CA / ACCESSWIRE / May 29, 2018 / Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today announced that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4th at 9:00a PDT / 12:00p EDT at the Luxe Sunset Bel Air Hotel in Los Angeles. Mr. Mark Guerin, Chief Financial Officer of Onconova, will be giving the presentation and meeting with investors. "The event is slated to be our largest Invitational to date," stated Chris Lahiji, President of LD Micro.

  • Who Are The Top Investors In Onconova Therapeutics Inc (NASDAQ:ONTX)?
    Simply Wall St.28 days ago

    Who Are The Top Investors In Onconova Therapeutics Inc (NASDAQ:ONTX)?

    In this analysis, my focus will be on developing a perspective on Onconova Therapeutics Inc’s (NASDAQ:ONTX) latest ownership structure, a less discussed, but important factor. When it comes to ownershipRead More...

  • ACCESSWIRElast month

    Free Technical Insights on OPKO Health and Three Other Biotech Stocks

    Stock Research Monitor: NBIX, NVAX, and ONTX LONDON, UK / ACCESSWIRE / May 22, 2018 / If you want a free Stock Review on OPK sign up now at www.wallstequities.com/registration . On Monday, benchmark US ...

  • Thomson Reuters StreetEventslast month

    Edited Transcript of ONTX earnings conference call or presentation 15-May-18 1:00pm GMT

    Q1 2018 Onconova Therapeutics Inc Earnings Call

  • GlobeNewswirelast month

    Onconova Therapeutics, Inc. Reports Business Highlights and Financial Results for First Quarter 2018

    NEWTOWN, Pa., May 15, 2018-- Onconova Therapeutics, Inc., a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary ...

  • Analysts Expect Breakeven For Onconova Therapeutics Inc (NASDAQ:ONTX)
    Simply Wall St.last month

    Analysts Expect Breakeven For Onconova Therapeutics Inc (NASDAQ:ONTX)

    Onconova Therapeutics Inc’s (NASDAQ:ONTX): Onconova Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. The US$28.47M market-cap company announced a latestRead More...

  • GlobeNewswirelast month

    Onconova Therapeutics, Inc. to Provide Corporate Update and First Quarter 2018 Financial Results

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes, today announced that the Company will release its first quarter 2018 financial results on May 15, 2018 before the market opens. The Company will host a conference call on May 15, 2018 at 9:00 a.m. Eastern Time to discuss these results.

  • GlobeNewswire2 months ago

    Onconova Therapeutics to Present at the Disruptive Growth and Healthcare Conference on May 8th, 2018

    Onconova Therapeutics, Inc. (ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), announced that the Company will present and meet investors at the 2018 Disruptive Growth and Healthcare Conference in New York City.  Dr. Ramesh Kumar, President & CEO, will present at the event.